216 related articles for article (PubMed ID: 25455505)
21. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy.
Kalender E; Zeki Celen Y; Elboga U; Deniz Demir H; Yilmaz M
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):328-31. PubMed ID: 23084016
[TBL] [Abstract][Full Text] [Related]
22. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
[TBL] [Abstract][Full Text] [Related]
23. [Multi-modality therapy concept in metastatic follicular thyroid carcinoma with hyperthyroidism].
Brauckhoff M; Dorsch K; Hädecke J; Kujat C; Straube F; Krause U; Dralle H
Chirurg; 2001 Jan; 72(1):37-42. PubMed ID: 11225454
[TBL] [Abstract][Full Text] [Related]
24. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
25. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
26. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine.
Sisson JC; Dewaraja YK; Wizauer EJ; Giordano TJ; Avram AM
Thyroid; 2009 Mar; 19(3):297-303. PubMed ID: 19207003
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
28. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
29. [Tracheostomy cannula as a cause of false positive result on the whole-body scan with (131)I in the follow-up of differentiated thyroid cancer].
Vallejo Casas JA; Mena Bares ML; Gálvez Moreno MA; Latre Romero JM
Rev Esp Med Nucl; 2011; 30(6):384-5. PubMed ID: 21546127
[No Abstract] [Full Text] [Related]
30. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
32. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
33. Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report.
Ogawa Y; Sugawara T; Seki H; Sakuma T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):302-5. PubMed ID: 16794352
[TBL] [Abstract][Full Text] [Related]
34. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
35. Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases.
Haq M; Hyer S; Flux G; Cook G; Harmer C
Br J Radiol; 2007 Feb; 80(950):e38-43. PubMed ID: 17495053
[TBL] [Abstract][Full Text] [Related]
36. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
37. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
39. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
40. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
